|
Market Closed -
Nasdaq
01:30:00 11/03/2026 am IST
|
5-day change
|
1st Jan Change
|
|
1.770 USD
|
+6.63%
|
 |
-4.84%
|
+31.11%
|
|
09/03 |
312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.
|
CI
| |
09/03 |
Certain Warrants of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.
|
CI
| |
09/03 |
Certain Performance Stock Units of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.
|
CI
| |
09/03 |
Certain Restricted Stock Units. of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.
|
CI
| |
04/03 |
Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
04/03 |
Ocugen, Inc., Q4 2025 Earnings Call, Mar 04, 2026
| | |
04/03 |
Ocugen: Q4 Earnings Snapshot
|
AQ
| |
04/03 |
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
|
GL
| |
03/03 |
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
|
AQ
| |
02/03 |
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
|
GL
| |
02/03 |
Ocugen Announces Phase 3 Limelight Enrollment Completion for Ocu400, A Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
|
CI
| |
18/02 |
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
|
GL
| |
09/02 |
Ocugen, Inc. Announces Executive Changes, Effective February 9, 2026
|
CI
| |
09/02 |
Ocugen Names Rita Johnson-Greene as CFO
|
MT
| |
09/02 |
Ocugen appoints Rita Johnson-Greene to chief financial officer
|
RE
| |
09/02 |
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
|
GL
| |
09/02 |
Ocugen, Inc. Appoints Rita Johnson-Greene as Chief Financial Officer
|
CI
| |
23/01 |
Ocugen Closes $20.9 Million Registered Direct Offering
|
MT
| |
23/01 |
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
|
GL
| |
21/01 |
Ocugen Prices $22.5 Million Stock Offering
|
MT
| |
21/01 |
Ocugen announces pricing of $22.5 million offering of common stock
|
RE
| |
21/01 |
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
|
GL
| |
15/01 |
Ocugen, Inc. - Special Call
| | |
15/01 |
Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial
|
MT
| |
15/01 |
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
